Profile data is unavailable for this security.
About the company
Sirnaomics Ltd. is an investment holding company. The Company and its subsidiaries are clinical-stage biotechnology companies that are engaged in developing and commercializing ribonucleic acid interference (RNAi) technology and multiple therapeutics. The Company is engaged in discovering and developing drugs for indications with unmet medical needs in areas. Its lead clinical drug candidates include STP705 and STP707. Its STP705 is a sterile drug product for the treatment of nonmelanoma skin cancer (NMSC), including squamous cell carcinoma in situ and basal cell carcinoma (BCC), recurrent keloids after keloidectomy, hypertrophic scar (HTS) and solid liver tumors, as well as for medical aesthetics. Its STP707 is a sterile drug product for the treatment of solid tumors, including liver cancer, metastatic cutaneous squamous-cell skin cancer (cSCC) and non-small cell lung cancer. It is capitalizing on its dual delivery platforms, which include Polypeptide nanoparticle (PNP) and GalAhead.
- Revenue in HKD (TTM)0.00
- Net income in HKD-614.84m
- Incorporated2007
- Employees145.00
- LocationSirnaomics Ltd401 Professional Drive, Suite 280GAITHERSBURG 20879United StatesUSA
- Websitehttps://www.sirnaomics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Uni-Bio Science Group Ltd | 484.72m | 70.88m | 400.63m | 407.00 | 5.83 | 1.59 | 4.57 | 0.8265 | 0.0111 | 0.0111 | 0.0762 | 0.041 | 1.38 | 2.62 | 13.50 | 1,190,953.00 | 20.18 | 1.46 | 28.50 | 1.97 | 81.04 | 80.59 | 14.62 | 1.23 | 1.76 | 97.93 | 0.1796 | 0.00 | 10.08 | 29.08 | 84.04 | -- | 84.98 | -- |
Kintor Pharmaceutical Ltd | 0.00 | -1.14bn | 541.47m | 225.00 | -- | 1.10 | -- | -- | -2.67 | -2.67 | 0.00 | 1.10 | 0.00 | 0.1448 | -- | 0.00 | -72.55 | -50.15 | -89.09 | -58.43 | -- | -27.62 | -- | -10,511.41 | 2.10 | -- | 0.3566 | -- | -- | -- | -11.15 | -- | -32.49 | -- |
Clover Biopharmaceuticals Ltd | 42.37m | -149.52m | 544.76m | 387.00 | -- | -- | -- | 12.86 | -0.1197 | -0.1197 | 0.034 | -0.6102 | 0.0116 | 0.0098 | 0.7449 | 109,476.80 | -4.08 | -- | -16.40 | -- | 61.75 | -- | -352.92 | -- | 0.5281 | -1.45 | -- | -- | -- | -- | 94.35 | -- | -- | -- |
Tianda Pharmaceuticals Ltd | 532.09m | -24.16m | 548.26m | 863.00 | -- | 0.926 | 48.08 | 1.03 | -0.0112 | -0.0112 | 0.2475 | 0.2754 | 0.5306 | 4.88 | 4.37 | 616,557.40 | -2.49 | -- | -3.84 | -- | 48.02 | -- | -4.70 | -- | 0.8907 | -13.98 | 0.161 | -- | -- | -- | -- | -- | -- | -- |
Sirnaomics Ltd | 0.00 | -614.84m | 611.72m | 145.00 | -- | 1.95 | -- | -- | -8.08 | -8.08 | 0.00 | 3.58 | 0.00 | -- | -- | 0.00 | -70.91 | -- | -71.22 | -- | -- | -- | -- | -- | -- | -- | 0.6176 | -- | -- | -- | 10.88 | -- | -- | -- |
Antengene Corporation Ltd | 72.64m | -627.26m | 654.64m | 201.00 | -- | 0.5286 | -- | 9.01 | -1.02 | -1.02 | 0.1181 | 1.83 | 0.0358 | 0.9773 | 3.41 | 361,400.90 | -30.91 | -53.57 | -36.46 | -58.94 | 81.74 | -- | -863.51 | -1,987.01 | 6.43 | -- | 0.1491 | -- | -57.97 | -- | 3.38 | -- | 202.03 | -- |
Genor Biopharma Holdings Ltd | 0.00 | -727.83m | 658.00m | 104.00 | -- | 0.5025 | -- | -- | -1.44 | -1.44 | 0.00 | 2.55 | 0.00 | 0.00 | -- | 0.00 | -37.91 | -55.46 | -44.02 | -63.73 | -- | 66.56 | -- | -14,819.18 | 5.38 | -- | 0.006 | -- | -100.00 | -- | 7.65 | -- | -48.85 | -- |
Lee's Pharmaceutical Holdings Ltd | 1.05bn | 16.70m | 706.60m | 1.06k | 42.31 | 0.3466 | 4.53 | 0.671 | 0.0284 | 0.0284 | 1.79 | 3.46 | 0.3713 | 1.83 | 10.75 | 996,247.90 | 0.7033 | 13.33 | 0.88 | 17.76 | 52.35 | 61.92 | 1.89 | 36.20 | 0.5526 | 3.90 | 0.0943 | 3.59 | -14.61 | -1.53 | -67.44 | -47.49 | -12.19 | -31.34 |
Transcenta Holding Limited | 58.12m | -499.25m | 720.02m | 215.00 | -- | 0.6474 | -- | 12.39 | -1.23 | -1.23 | 0.1428 | 2.55 | 0.0281 | 2.05 | 1.49 | 270,319.30 | -24.17 | -- | -33.97 | -- | 26.74 | -- | -859.01 | -- | 1.20 | -32.87 | 0.285 | -- | -47.15 | -- | -13.72 | -- | -- | -- |
Pak Fah Yeow International Ltd | 259.16m | 105.04m | 766.63m | 102.00 | 7.30 | 1.00 | 6.82 | 2.96 | 0.337 | 0.337 | 0.8316 | 2.46 | 0.2995 | 2.88 | 22.18 | 2,540,765.00 | 12.14 | 3.99 | 12.60 | 4.18 | 84.45 | 80.79 | 40.53 | 21.27 | 6.90 | 10.08 | 0.0062 | 100.68 | 76.06 | 12.94 | 250.66 | 23.02 | 18.83 | -8.06 |
Jbm (Healthcare) Ltd | 610.30m | 97.99m | 792.12m | 258.00 | 8.74 | 0.8447 | 5.32 | 1.30 | 0.1087 | 0.1087 | 0.6786 | 1.12 | 0.4406 | 5.88 | 4.10 | 2,000,994.00 | 7.56 | 3.33 | 9.04 | 4.93 | 47.70 | 45.97 | 17.17 | 10.97 | 1.45 | 22.15 | 0.1211 | 13.81 | 28.11 | 14.51 | 131.90 | 6.14 | -5.09 | -- |
Zhaoke Ophthalmology Ltd | 20.24m | -415.57m | 813.75m | 313.00 | -- | 0.3681 | -- | 40.21 | -0.764 | -0.764 | 0.0372 | 4.05 | 0.0075 | -- | 0.531 | 64,653.92 | -15.43 | -- | -17.27 | -- | 75.98 | -- | -2,053.54 | -- | 5.32 | -47.54 | 0.1041 | -- | -- | -- | 5.47 | -- | -- | -- |
Jilin Provnc Hnn Chnglng Bio-pharm CoLtd | 908.27m | 159.96m | 840.38m | 848.00 | 5.25 | 0.526 | 6.86 | 0.9253 | 0.2855 | 0.2855 | 1.62 | 2.85 | 0.3587 | 2.18 | 2.94 | 1,071,074.00 | 6.32 | 7.67 | 9.12 | 10.48 | 69.40 | 78.79 | 17.61 | 20.68 | 1.51 | -- | 0.0515 | 7.22 | -0.0049 | 5.38 | -23.43 | -1.67 | -1.14 | -- |
Fusen Pharmaceutical Co Ltd | 610.45m | -39.15m | 884.95m | 1.15k | -- | 1.46 | -- | 1.45 | -0.0524 | -0.0524 | 0.8117 | 0.811 | 0.4199 | 1.95 | 8.36 | 531,755.00 | -2.69 | 0.9678 | -5.54 | 1.74 | 52.95 | 51.95 | -6.42 | 2.59 | 0.6096 | 0.756 | 0.3797 | 27.95 | 15.02 | 4.13 | -4.83 | -- | 0.2124 | -- |
Brii Biosciences Ltd | 665.92k | -188.69m | 890.37m | 128.00 | -- | 0.2643 | -- | 1,337.05 | -0.2594 | -0.2594 | 0.0009 | 4.62 | 0.0002 | -- | -- | 5,202.51 | -5.60 | -- | -5.84 | -- | -- | -- | -29,881.69 | -- | -- | -- | 0.001 | -- | -98.80 | -- | 63.90 | -- | -- | -- |
Zhongzhi Pharmaceutical Holdings Ltd | 2.21bn | 175.68m | 898.14m | 2.64k | 5.01 | 0.7937 | 3.12 | 0.406 | 0.2074 | 0.2074 | 2.61 | 1.31 | 1.12 | 2.53 | 10.54 | 837,056.60 | 8.95 | 7.69 | 14.15 | 11.75 | 59.73 | 60.44 | 8.01 | 6.73 | 0.894 | -- | 0.1424 | 42.46 | 12.26 | 12.41 | 53.00 | 13.86 | 17.65 | 3.22 |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 09 May 2024 | 2.46m | 2.81% |
GF Fund Management Co., Ltd.as of 31 Dec 2023 | 738.65k | 0.84% |
Norges Bank Investment Managementas of 31 Dec 2023 | 657.30k | 0.75% |
Bosera Asset Management Co., Ltd.as of 31 Dec 2022 | 633.45k | 0.72% |
Charles Schwab Investment Management, Inc.as of 09 May 2024 | 136.81k | 0.16% |
SSgA Funds Management, Inc.as of 09 May 2024 | 74.15k | 0.09% |
China Universal Asset Management Co., Ltd.as of 31 Dec 2023 | 45.80k | 0.05% |
Vanguard Global Advisers LLCas of 30 Apr 2024 | 20.40k | 0.02% |
E Fund Management Co., Ltd.as of 31 Dec 2023 | 2.47k | 0.00% |